Full text is available at the source.
Abstract
Polycystic ovary syndrome (PCOS), also referred to as polyendocrine metabolic ovarian syndrome (PMOS), is associated with reproductive and cardiometabolic complications.
- PCOS is linked to challenges in reproduction and heart-related health issues.
- Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) receptor agonists may enhance outcomes related to obesity.
- The effects of GLP-1 and GIP receptor agonists on pregnancy outcomes in individuals with PMOS are not yet clear.
Simplified